New to MAMA
Thank you for visiting the MAMA website!
Introduction to the MAMA Study
The MAMA Study is designed to find out whether it is better for women who have inflammatory arthritis and are pregnant to temporarily stop or to continue taking biologic medications. Currently, both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK; this varies between different hospitals around the UK. The MAMA Study is looking to provide an answer on which is the better approach.
Your participation
Women who take part in the MAMA Study will be randomly allocated by a computer system to one of the following groups:
The continuing group. Women in this group will continue taking their biologic thoughout pregnancy.
OR
The stopping group. Women in this group will stop their biologics before the third trimester (28 weeks) of pregnancy, and restart no earlier than 2 weeks post-pregnancy.
Other than stopping or continuing your current biologic by 28 weeks' gestation, no other changes will be made to your arthritis treatment as a result of being in this study.
Both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK.
There are short questionnaires to fill out when you join the study, monthly during pregnancy and at 3, 6, 12, and 24 months after your baby is born. These questionnaires will ask you about your arthritis symptoms and treatment, and about you and your child's health and quality of life.
Your baby's involvement
There will also be an option for your baby to be considered for another part of the study looking at your baby's immune system.
Further information
For further information about the study, please see the MAMA Participant Information Leaflet.
